Related Experiment Video

Updated: Aug 28, 2025

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

9.9K

Advances in Engineered Biomaterials Targeting Angiogenesis and Cell Proliferation for Cancer Therapy

Poonam Yadav1, Chhavi Dua1, Avinash Bajaj1

  • 1Laboratory of Nanotechnology and Chemical Biology, Regional Centre for Biotechnology, NCR Biotech Science Cluster, 3rd Milestone Faridabad - Gurgaon Expressway, Faridabad, 121001, India.

Chemical Record (New York, N.Y.)
|September 14, 2022
PubMed

Insights

Engineered biomaterials offer a promising solution for codelivering chemotherapy and anti-angiogenic agents, overcoming systemic toxicity and improving cancer treatment efficacy.

Area of Science:

  • Biomedical Engineering
  • Drug Delivery Systems
  • Cancer Therapeutics

Background:

  • Combination therapy using antiangiogenic agents and chemotherapy is effective for cancer treatment.
  • Non-specific biodistribution of combination therapy leads to systemic toxicity.
  • Biomaterial-mediated codelivery can enhance tumor targeting and therapeutic outcomes.

Purpose of the Study:

  • To review advances in engineered biomaterials for codelivering anti-cancer and anti-angiogenic agents.
  • To discuss strategies for targeting both angiogenesis and cell proliferation in cancer therapy.

Main Methods:

  • Review of liposome, hydrogel, and micelle-based biomaterials for drug codelivery.
  • Analysis of nanoparticles engineered for targeted delivery of combination therapies.
  • Exploration of siRNA-based strategies for targeting angiogenesis.

Main Results:

  • Engineered biomaterials demonstrate potential for improved drug accumulation at tumor sites.
  • Codelivery systems can overcome limitations of non-specific biodistribution and systemic toxicity.
  • Advances in nanoparticle and siRNA delivery show promise for enhanced cancer treatment.

Conclusions:

  • Engineered biomaterials are crucial for effective codelivery of combination cancer therapies.
  • Targeting angiogenesis and cell proliferation simultaneously offers a promising therapeutic strategy.
  • Further development of biomaterial-mediated codelivery systems is essential for advancing cancer treatment.
Keywords:
AngiogenesisAnticancer DrugsCancerHydrogelsNanomicellesNanoparticles

More Related Videos

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles09:01

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles

Published on: September 27, 2013

11.2K
Visualizing Angiogenesis by Multiphoton Microscopy In Vivo in Genetically Modified 3D-PLGA/nHAp Scaffold for Calvarial Critical Bone Defect Repair09:34

Visualizing Angiogenesis by Multiphoton Microscopy In Vivo in Genetically Modified 3D-PLGA/nHAp Scaffold for Calvarial Critical Bone Defect Repair

Published on: September 7, 2017

9.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.7K
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.8K
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K